UA-45667900-1

Sunday, 5 July 2026

Overcoming Picky Eating and ARFID: What the Latest Research Tells Parents

 

  

A few days ago I read a comment from the parent of an autistic teenager that perfectly illustrates why we should never assume that a restricted diet is permanent.

Six years ago, their son ate only a handful of foods. Every meal was a battle. Introducing anything new seemed impossible. Family meals revolved around avoiding conflict, and eating outside the home was stressful for everyone.

Today, that same young man eats what most people would consider a perfectly normal adult diet. Vegetables, fish, different cuisines and healthy foods that once seemed unimaginable are now part of everyday life.

Nothing miraculous happened.

There was no breakthrough drug.

There was no secret supplement.

There were simply six years of patient, structured work by parents who refused to believe that their child's beige diet was fixed forever.

The journey was not easy. There were setbacks, disappointments and many failed attempts. Progress was measured in months and years rather than days and weeks.

But they never stopped trying.

Their story reminds us of something that is easy to forget. Today's diet does not have to be tomorrow's diet

That message is particularly timely because a major randomized clinical trial from Stanford University has just provided the strongest evidence yet that parents themselves can play a central role in helping children with ARFID make meaningful progress.

 

Three Messages I Hope Every Parent Remembers

If you read nothing else in this article, I hope you remember these three ideas.

 

First, ARFID is an observation, not an explanation.

It describes a child's eating behaviour, but it does not explain why that behaviour exists.

 

Second, ARFID is a diagnosis, not a prognosis.

Receiving the diagnosis tells you where your child is today. It says very little about where they could be five years from now.

 

Third, parents are not passive observers.

The strongest clinical evidence we now have suggests that parents are one of the most important parts of the treatment.

These three ideas underpin everything that follows.

 

ARFID Is a Diagnosis, Not a Prognosis

Avoidant Restrictive Food Intake Disorder (ARFID) was only added to the Diagnostic and Statistical Manual (DSM-5) in 2013. Before then, many children were simply described as "extremely picky eaters."

The diagnosis has been helpful because it acknowledges that severe food restriction is a genuine medical and psychological problem rather than simply bad behaviour or poor parenting.

However, diagnoses can sometimes have unintended consequences.

Some parents hear the word ARFID and begin to think that their child's eating habits are largely fixed.

That is understandable, but it is not what the diagnosis means.

ARFID tells us that eating has become sufficiently restricted to affect health, growth or everyday life.

It does not tell us why.

Nor does it tell us what the future holds.

In medicine we often confuse diagnosis with prognosis.

The two are completely different.

A diagnosis describes today's problem.

A prognosis attempts to predict tomorrow.

The Stanford study—and many individual family experiences—suggest that today's eating habits should not be viewed as a reliable predictor of where a child may be after several years of appropriate intervention.

 

Why Expectations Matter

One lesson I have learned from writing this blog is that expectations matter.

Not because optimism magically changes biology, but because expectations influence how much effort people are prepared to invest.

Autism provides many examples.

Poor handwriting is extremely common. Motor planning, muscle control and coordination are often affected.

Yet many autistic children spend years practising handwriting and eventually develop neat, legible writing. The neurological differences have not disappeared. The skill has improved.

Toilet training provides another example.

Some autistic children remain in diapers/nappies or pull-ups for years because everyone assumes they simply are not ready.

Other families invest months—or sometimes years—using structured toilet-training programs.

Not every child achieves complete independence or perfect handwriting.

But many achieve far more than anyone initially thought possible.

Eating should be viewed in exactly the same way.

It is another developmental skill.

Some children acquire it naturally.

Others require hundreds or even thousands of opportunities to practise.

Of course, families differ enormously.

Parents working full-time, caring for several children or home-schooling may genuinely struggle to devote the time required for intensive feeding programmes.

Those constraints are real and deserve understanding.

However, where circumstances allow, an ARFID diagnosis should encourage parents to increase their efforts—not reduce their expectations.

The diagnosis should increase expectations for intervention, not lower expectations for progress.

 

How Common Are Picky Eating and ARFID?

Picky eating is almost a normal part of childhood.

Around one quarter of young children go through a period when they refuse many foods. Fortunately, most gradually grow out of it.

Autism is different. Depending on the study, between 46% and nearly 90% of autistic children show significant food selectivity.

For some children this simply means having a short list of preferred foods.

For others, eating becomes so restricted that nutritional deficiencies develop, weight falters or everyday family life becomes dominated by food.

This is where ARFID begins.

Rather than being a completely separate condition, it is often helpful to think of ARFID as representing the severe end of a spectrum.

Normal childhood picky eating lies at one end.

Severe nutritional compromise lies at the other.

 

ARFID Is an Observation, Not an Explanation

Perhaps the most important question parents should ask is not:

"Does my child have ARFID?"

Instead ask:

"Why does my child have ARFID?"

The diagnosis simply tells us what is happening.

It does not explain why.

In autistic children there are often multiple contributing factors.

Some children have genuine sensory hypersensitivity.

Textures that seem perfectly ordinary to us may feel intensely unpleasant to them.

Others have chronic gastrointestinal discomfort.

Reflux, constipation, delayed stomach emptying and eosinophilic esophagitis can all make eating uncomfortable.

If every meal is associated with discomfort, avoiding food becomes entirely understandable.

Children with connective tissue disorders such as hypermobile Ehlers-Danlos syndrome, or milder extracellular matrix abnormalities, may also develop gastrointestinal dysmotility, reflux and abdominal pain. These conditions are increasingly recognised in autism and may contribute to restricted eating in a subgroup of children.

Oral-motor difficulties are another overlooked cause.

Some children struggle to chew particular textures efficiently, making certain foods genuinely difficult rather than simply disliked.

Anxiety also plays an important role.

A frightening choking episode or severe vomiting illness can lead to persistent fear of eating.

Finally, nutritional deficiencies themselves may worsen the problem.

Iron deficiency, zinc deficiency and other micronutrient deficiencies can alter taste perception, appetite and energy levels, creating a vicious cycle in which poor diet perpetuates itself.

The important message is this:

Finding one of these biological problems does not mean behavioural therapy is unnecessary.

It means behavioural therapy is more likely to succeed once the underlying problem is treated.

Medical treatment and feeding therapy should not be viewed as competing approaches.

In many children they complement one another.

 

Has modern food made ARFID more common?

One question that is rarely discussed is whether modern food itself may unintentionally reinforce food selectivity.

Many processed foods are engineered to be identical every single time.

Every chip/crisp tastes the same.

Every chicken nugget has the same texture.

Every biscuit/cookie feels identical.

Fresh food is completely different.

One strawberry is sweeter than the next.

One apple is crisp while another is soft.

Even two bananas picked from the same bunch taste slightly different.

For children who crave predictability, processed foods offer exactly that.

Nature does not.

This raises an interesting possibility.

Could a highly processed diet make it even harder for some children to accept the natural variability of real food?

We do not yet know the answer.

But it is certainly an area worthy of research.

 

Why dietary diversity matters

The goal of feeding therapy is not simply to make the list of accepted foods longer.

The goal is to improve health.

A child who expands their diet from five processed beige foods to ten processed beige foods has certainly made progress—but probably not enough.

The greatest benefits come from gradually introducing foods that provide nutrients missing from the existing diet.

Vegetables.

Fruit.

Fish.

Legumes.

Nuts.

Seeds.

Fermented foods.

Whole grains.

Each contributes something different.

Dietary diversity also feeds the gut microbiome.

Different bacteria thrive on different fibres and plant compounds. A monotonous diet supports a relatively monotonous microbiome.

Every additional plant food potentially feeds different bacterial species.

Given the growing evidence linking the gut microbiome to immune function, gastrointestinal health and possibly even brain function, this may become one of the most important long-term benefits of improving diet.

For autistic children, a broader diet may improve growth, bone health, immune function, gastrointestinal health and reduce nutritional deficiencies.

The goal is not simply to produce a child who eats more foods.

The goal is to produce a healthier child.

 

When does ARFID become dangerous?

Not every child who is a picky eater has ARFID.

Many children survive for years on a limited selection of foods and continue to grow normally. Although parents understandably worry, these children often improve naturally as they get older.

ARFID becomes a medical disorder when food restriction begins to cause significant problems. These may include:

  • Poor weight gain or weight loss
  • Slowed growth
  • Nutritional deficiencies (iron, zinc, vitamin D, vitamin C and others)
  • Dependence on nutritional supplements or tube feeding
  • Extreme anxiety surrounding meals
  • Family life becoming dominated by food

The distinction is important because the goal is not to pathologize every fussy eater. It is to identify children whose restricted eating is affecting their health or development.

Fortunately, even severe ARFID is treatable.

 

The Stanford Randomized Trial

The best evidence to date comes from researchers at Stanford University, who recently completed the first large randomized controlled trial of a treatment called ARFID Parent Training Protocol (ARFID-PTP).

Rather than providing months of intensive therapy directly to the child, the researchers trained parents.

This is a subtle but important shift.

Instead of trying to change the child during a one-hour therapy session each week, parents learn how to create hundreds of learning opportunities during normal family life.

The study involved 105 children aged 5–12 years with ARFID.

Families were randomly assigned either to receive the parent-training programme or to continue with usual care.

After six months, the differences were striking.

Children whose parents received the training accepted significantly more new foods, had fewer ARFID symptoms and were more likely to no longer meet diagnostic criteria for ARFID.

Perhaps even more impressive was that parents themselves became more confident and less anxious about feeding.

The therapy had changed not only children's behaviour but also the behaviour of the adults supporting them.

That may be one reason it worked so well.

 

The Therapist Becomes the Coach

Traditionally we imagine therapy as something that happens inside a clinic.

A therapist works with a child while parents wait outside.

Feeding therapy is different.

The therapist's real job is often to coach the parents.

Parents are present at breakfast.

Parents are present at lunch.

Parents are present at dinner.

That means they have thousands of opportunities each year to reinforce progress.

A therapist may only have fifty hours with a child over an entire year.

Parents may have over one thousand mealtimes.

Once parents understand the principles, they become the treatment.

The Stanford study confirms what many experienced feeding therapists have believed for years: empowering parents may be one of the most effective interventions available. 


Two treatments help ARFID, a common pediatric eating disorder, Stanford Medicine trial shows


Family vs Individual Treatment for Children With Avoidant/Restrictive Food Intake Disorder: A Randomized Clinical Trial

To examine the comparative efficacy of Family-based Treatment for Avoidant/Restrictive Food Intake Disorder (FBT-ARFID) to individual Psychoeducational Motivational Therapy (PMT) for underweight children with ARFID between the ages of 6 and 12 years of age. The main outcome evaluated was the difference between groups on change in percent estimated body weight (%EBW) from baseline (BL) to end of treatment (EOT).

Method

Ninety-eight children with ARFID were randomized to 14 sessions over 4 months of telehealth FBT-ARFID or PMT. Assessments of weight/height, eating-related cognitions, and behaviors associated with ARFID were collected online at BL, 1 month, 2 months, and EOT by assessors masked to treatment condition.

Results

FBT-ARFID was superior to PMT at the EOT in promoting increased %EBW. There were no differences between groups on improvements in overall severity of ARFID symptoms or other related ARFID symptoms; however, BL severity of ARFID symptoms moderated the effect, with children who were most symptomatic improving significantly more in FBT-ARFID than in PMT (exploratory analyses).

Conclusion

FBT-ARFID is superior to PMT for promoting weight gain in low-weight children with ARFID, especially for those children with greater severity of ARFID symptoms.

 

 

What Feeding Therapy Actually Involves

Many people imagine feeding therapy consists of persuading a child to eat vegetables.

In reality, it is usually much more gradual.

A child may first learn simply to tolerate a new food on the table.

Next they might touch it.

Then smell it.

Then lick it.

Eventually they may hold it in their mouth before spitting it out.

Only much later do they swallow it.

Each of these tiny steps represents progress.

Therapists often describe this as systematic desensitisation.

The child slowly learns that new foods are safe.

Repeated exposure gradually reduces anxiety.

The process resembles treatment for phobias.

Nobody expects someone with a fear of spiders to begin by holding a tarantula.

Instead, they gradually become comfortable with increasingly challenging situations.

Eating works in much the same way.

 

Why repeated exposure changes the brain

Parents often become discouraged after offering a new food ten or twenty times without success.

Unfortunately, that may not be nearly enough.

Research on food acceptance suggests that some children need dozens—or even hundreds—of exposures before a new food becomes familiar.

Every successful exposure teaches the brain something important:

"Nothing bad happened."

Over time, anxiety decreases.

Novelty decreases.

The food becomes part of the child's "safe" repertoire.

This is why consistency matters so much.

Small gains repeated hundreds of times eventually become major changes.

The six-year success story that opened this article probably consisted of thousands of tiny victories that, on their own, hardly seemed worth celebrating.

Together, they transformed a life.

 

Case histories teach us what clinical trials cannot

Clinical trials tell us what usually happens.

Individual families remind us what is possible.

The parent whose story inspired this article did not achieve success in six weeks.

They achieved it in six years.

That distinction matters.

Modern medicine often expects rapid results.

Parents understandably hope that one supplement, one therapy or one new technique will produce dramatic improvements within a few months.

Development rarely works that way.

Children learn through repetition.

Brains change through repetition.

Skills improve through repetition.

Eating is no different.

Some children will improve quickly.

Others will take years.

The important thing is that progress remains possible.

 

Progress Is Measured in Years

One reason families abandon feeding programmes is that they judge progress too soon.

Imagine expecting a child to learn the piano after six lessons.

Or expecting fluent reading after one month at school.

We would never make those assumptions.

Yet many people expect eating habits to change within weeks.

Instead, it is more realistic to ask:

"Is my child eating more different foods this year than last year?"

That question shifts the focus away from daily frustrations and towards long-term development.

The family who achieved success over six years almost certainly experienced long periods where nothing appeared to change.

But change was happening.

It was simply happening slowly.

 

Conclusion

Reading the six-year success story and then reading the Stanford trial left me with the same conclusion.

Parents matter.

Not because they caused ARFID.

Not because they are expected to fix it overnight.

But because they are uniquely placed to help their child improve every single day.

An ARFID diagnosis should never be interpreted as a prediction of lifelong eating difficulties.

Instead, it should be viewed as the starting point for understanding why eating has become difficult and for developing a structured plan to improve it.

For some children, that means treating reflux, constipation or nutritional deficiencies.

For others, it means addressing anxiety or oral-motor problems.

For almost all children, it means creating repeated opportunities to experience new foods without fear.

The therapist may design the programme.

The doctor may identify underlying medical problems.

But it is parents who provide the thousands of moments in which change actually happens.

As the family who inspired this article discovered, those moments accumulate.

One new food becomes two.

Two become ten.

Ten become a varied and healthy diet.

It may take years.

There will almost certainly be setbacks.

Progress may be frustratingly slow.

An eight-year-old with a poor diet and sloppy handwriting can become a teenager with a healthy diet and neat handwriting. Much depends on empowering parents with the knowledge, confidence and practical strategies to guide that journey.

As you embark on that journey, choose your community wisely. Social media can be an invaluable source of shared experience, but it can also become an echo chamber of low expectations. Look for communities that acknowledge today's challenges while continuing to believe in tomorrow's possibilities. Surround yourself with people who encourage evidence-based action, persistence and hope, rather than resignation.

Today's restricted eater does not have to remain tomorrow's restricted eater.




Thursday, 25 June 2026

Elevated microbially-derived metabolites in autism

 

 

 

A new study reports that many children with autism have elevated levels of microbially-derived metabolites (MDMs) in their urine. The authors propose that this pattern is so common that it defines a distinct subtype of autism, which they call ASD-MDM (Autism Spectrum Disorder associated with Microbially-Derived Metabolites).

The authors claim that approximately 90% of autistic children have ASD-MDM and also suggest that ASD-MDM is a distinct subtype of autism. But that would mean almost all autism is ASD-MDM, so it would not really be a focused sub-type. 

It is striking that there are 22 authors listed, but only 52 ASD children studied. There are some familiar names among the 22.


Elevated microbially-derived metabolites in autism: a possible diagnostic screening test for a distinct ASD phenotype


The study is interesting and deserves attention. However, like many autism studies, it raises as many questions as it answers.

 

What did the researchers find?

The researchers measured a range of metabolites produced by gut bacteria and yeasts in the urine of 52 children with autism and 47 typically developing controls.

The metabolites fell into three broad categories:

  • Phenylalanine and tyrosine-derived metabolites such as p-cresol and p-cresol sulfate
  • Tryptophan-derived metabolites such as indoxyl sulfate and various indole compounds
  • Yeast-associated metabolites such as arabinitol

Many of these compounds were significantly elevated in the autism group.

The most convincing findings involved p-cresol, p-cresol sulfate, phenylacetylglutamine and indoxyl sulfate. These metabolites have been reported repeatedly in previous autism studies and are among the best-replicated metabolic findings in the autism literature.

Using a scoring system based on the number of metabolites exceeding the range seen in any control child, the authors reported that approximately 78–90% of children with autism had at least one markedly elevated microbial metabolite.

 

What is new?

The most important contribution of this study is not the individual metabolites. We have known about elevated p-cresol for many years. It has been covered extensively in previous posts and in Stephen’s comments.

The novelty lies in combining multiple microbial metabolites into a single framework and proposing that they collectively define a biological subtype of autism.

This is an attractive idea.

Autism is clearly not a single disorder. Two people can receive the same diagnosis while having entirely different underlying biology. One person may have a monogenic disorder, another a mitochondrial dysfunction, another a channelopathy, and another an immune-mediated condition.

The notion that a substantial subgroup of autistic children may have a characteristic pattern of microbial metabolites is therefore entirely plausible.

 

Reasons for caution

The authors make some ambitious claims regarding diagnosis and screening. Several limitations should be kept in mind.

First, the study was very small, involving just under one hundred participants. This is adequate for a pilot study, but much too small to establish a diagnostic test with confidence.

Second, the control group was unusual. The autism group was predominantly male, which is expected, but the control group contained more females than males. This creates the possibility that some of the observed differences may be influenced by sex-related differences rather than autism alone. Comparing autistic boys with very restricted diets to typical girls with rich varied diets, springs to mind.


Sex Distribution of Study Participants
ASD Group Typically Developing (TD) Controls
Male 41 20
Female 11 27
Total 52 47
Male (%) 79% 43%
Female (%) 21% 57%
Male:Female Ratio 3.7:1 0.74:1


Third, the study collected no information on diet or medication use. This is a major limitation. Many autistic children have restricted diets, gastrointestinal problems, food selectivity, supplements or medications that can influence both the microbiome and the metabolome. Without these data, it is difficult to determine how much of the observed metabolic profile is attributable to autism itself.

Diet is one of the strongest known determinants of microbial metabolism. Many young autistic children, particularly those with more severe autism, consume highly restricted diets consisting of a small number of preferred "safe foods", often ultra-processed foods and very little dietary fiber. Such eating patterns can profoundly alter both the composition of the gut microbiome and the metabolites it produces. A boy whose diet consists largely of chicken nuggets, fries, white bread and sweetened drinks may be expected to have a very different microbiome from a girl consuming a varied diet rich in fruit, vegetables and fiber, regardless of whether either child has autism.

Super Size Me was a 2004 documentary by Morgan Spurlock in which he ate only food from McDonald's for 30 days.

The rules included:

Every meal had to come from McDonald's.

If asked whether he wanted to "super size" a meal, he had to accept.

He tried to eat three meals a day.

He reduced his exercise to match the average American activity level.

By the end of the month he reported:

·        Weight gain of about 11 kg (24 lb)

·        Increased cholesterol

·        Abnormal liver function tests

·        Reduced energy

·        Mood changes

If it had been 2026, they would have analyzed changes to his microbiome and looked at his urine metabolites. You can imagine the results.

The film became very influential and helped draw attention to the health effects of fast food.

 

Fourth, the study did not directly examine the gut microbiome. Instead, it measured microbial metabolites excreted in urine. Elevated urinary metabolites may reflect altered microbial activity, but can also be influenced by intestinal permeability, liver metabolism, sulfation capacity and kidney function. The study therefore provides direct evidence of altered metabolite profiles, but only indirect evidence of gut dysbiosis.

Finally, this was largely a study of classic childhood autism rather than the full autism spectrum. The participants were predominantly male and had an average CARS score of 41, consistent with substantial autistic symptoms  (A CARS score above about 37 is generally considered severe autism). The findings therefore cannot automatically be generalized to those with Level 1 or 2 autism, or those diagnosed later in life. It remains possible that elevated microbial metabolites are particularly common in children with more severe autism and gastrointestinal dysfunction.

 

Only urine was tested

An important limitation of this study is that the researchers did not directly examine the gut microbiome itself. They analyzed urine samples and measured concentrations of metabolites thought to be produced by gut bacteria or yeasts, such as p-cresol sulfate, p-cresol and indoxyl sulfate. This approach was chosen because these metabolites may provide a functional readout of microbial activity and can be measured using a simple, non-invasive urine test. However, elevated urinary metabolites do not necessarily prove the presence of gut dysbiosis, since their levels can also be influenced by diet, intestinal permeability, liver metabolism, sulfation capacity and kidney excretion.

A stronger study would have combined urinary metabolomics with stool microbiome sequencing, dietary assessments, medication histories and measurements of gastrointestinal symptoms. Such an integrated approach would have helped determine whether the abnormal metabolites truly arose from altered microbial populations and whether specific bacteria or fungi were responsible. Therefore, while the study provides convincing evidence that many autistic children have abnormal patterns of microbial metabolites, it provides only indirect evidence that gut dysbiosis itself is the underlying cause, and its conclusions should be interpreted accordingly.

  

Cause or consequence?

This is perhaps the most important question.

The paper often implies the following sequence:

Gut dysbiosis → microbial metabolites → autism

But the reverse sequence is also possible:

Autism → altered diet, gut motility and gastrointestinal function → microbial metabolites

The study cannot distinguish between these possibilities.

To demonstrate causation, researchers would need to identify elevated metabolites before autism symptoms emerge and show that those metabolites predict later diagnosis.

That would be a much stronger result.

 

Why this matters

Despite the limitations, this study fits remarkably well with a growing body of evidence suggesting that gut-derived metabolites can influence brain function.

P-cresol is particularly noteworthy because it has been associated with mitochondrial dysfunction, immune activation, impaired intestinal barrier function and behavioural abnormalities in animal models.

The repeated appearance of p-cresol and related compounds across many studies suggests that these findings should not be dismissed.

What remains unclear is whether these metabolites are merely biomarkers or whether they actively contribute to symptoms.

 

The broader perspective

Readers of this blog will know that I have never viewed autism as a single condition with a single treatment. Instead, I view autism as a behavioural diagnosis that sits on top of multiple underlying biological disorders.

Some people may have:

  • Mitochondrial dysfunction
  • Ion channel dysfunction
  • Folate pathway abnormalities
  • Neuroinflammation
  • Gastrointestinal dysfunction
  • Microbial metabolite abnormalities

and often several of these at the same time.

The goal should not be to debate whether autism is genetic or environmental, neurological or gastrointestinal.

The goal should be to identify the specific abnormalities present in each individual and address them where possible.

This study adds weight to the argument that microbial metabolism deserves investigation as part of that process.

 

The clinically important question

The most interesting question is not whether microbial metabolites can help diagnose autism.

The most important question is whether reducing abnormal metabolites improves symptoms.

If a child has markedly elevated p-cresol sulfate or indoxyl sulfate, can we normalize those levels?

If we do, does language improve? Does anxiety improve? Do gastrointestinal symptoms improve? Does adaptive functioning improve?

Those are the questions that matter to families.

The authors point to previous studies of microbiota transfer therapy that reported reductions in p-cresol sulfate accompanied by improvements in gastrointestinal and autism-related symptoms. Whether those findings can be replicated in larger controlled studies remains to be seen.

 

A look at the detailed results

 

Looking more closely at Tables 4 and 5

The paper presents two sets of metabolite data that are easy to confuse. Table 4 contains results from the initial semi-quantitative (untargeted) metabolomics analysis, while Table 5 contains results from the subsequent quantitative (targeted) analysis using authentic chemical standards.

Readers should focus primarily on Table 5, because it represents the validation phase of the study. Table 4 was designed to identify potentially interesting metabolites, but untargeted metabolomics is prone to both measurement error and occasional metabolite misidentification. In contrast, the metabolites in Table 5 were measured directly against known standards, allowing both their identity and concentration to be determined with much greater confidence.

In simple terms, Table 4 generated the hypotheses, while Table 5 tested them.

One of the most interesting aspects of the paper is that some dramatic findings from Table 4 became much less impressive in Table 5. Several tryptophan-derived metabolites appeared to increase by more than 1000% in the discovery phase, but these effects were greatly reduced or no longer statistically significant when measured using quantitative methods. This is not unusual and illustrates why validation studies are so important.

On the other hand, some findings survived the transition from discovery to validation. Most notably, p-cresol, p-cresol sulfate, phenylacetylglutamine and indoxyl sulfate remained significantly elevated in the autism group. These are therefore the metabolites that deserve the greatest attention.

The overall picture from comparing Tables 4 and 5 is that the evidence for widespread abnormalities in microbial metabolism remains convincing, but the evidence for some individual metabolites is weaker than the headline figures from the discovery phase might suggest. The quantitative data in Table 5 provide the most reliable basis for interpreting the study and assessing its clinical relevance.

 

Useful observations from Tables 4 and 5

1. p-Cresol survives both discovery and validation

The strongest finding is not a new metabolite but an old one.

In Table 4:

  • p-Cresol increased by 151%
  • p-Cresol sulfate increased by 54%

In Table 5:

  • p-Cresol increased by 76%
  • p-Cresol sulfate increased by 139%

Many findings became weaker during quantitative validation, but p-cresol and p-cresol sulfate remained significant. This strengthens the case that elevated p-cresol metabolism is a genuine feature of a subgroup of autistic children.

 

2. Phenylacetylglutamine may deserve more attention

Phenylacetylglutamine (PAGln) is increasingly recognized as a microbiome-derived metabolite with important biological effects.

In Table 4:

  • 64% increase
  • 32% of ASD children exceeded the highest control value

In Table 5:

  • 80% increase
  • Highly significant (p = 0.002)

Compared with p-cresol, PAGln receives relatively little attention in autism research but may prove to be an important marker of altered aromatic amino acid metabolism.

 

3. Tryptophan metabolism appears abnormal in many children

Although the individual metabolites differed between the two analyses, the overall signal remained.

The study reports:

  • 64% of ASD children with elevated tryptophan metabolites in Table 4
  • 42% in Table 5

This suggests that altered microbial metabolism of tryptophan may be common in autism. This is particularly interesting because tryptophan is the precursor of serotonin, melatonin and kynurenine pathway metabolites.

 

4. Indoxyl sulfate deserves attention

Indoxyl sulfate is another well-known microbial metabolite.

In Table 5:

  • 171% increase
  • Statistically significant (p = 0.03)

Like p-cresol sulfate, it has been linked to inflammation, oxidative stress and mitochondrial dysfunction. It may be one of the more biologically important findings in the study.

 

5. The abnormalities are highly heterogeneous

Perhaps the most important finding is that no individual metabolite identified most autistic children.

For example:

  • p-Cresol sulfate: 21% above the control range
  • p-Cresol: 19%
  • Hydroxybenzoic acid: 17%
  • Indole-3-acryloyl glycine: 17%
  • Arabinitol: 10%

Different children had different abnormalities. This strongly supports the view that autism consists of multiple biological subtypes rather than a single disorder with a single biochemical signature.

 

6. The yeast findings are relatively weak

The paper devotes considerable attention to yeast metabolites, but the quantitative data are less convincing.

Only arabinitol remained significant in Table 5. Other proposed yeast markers, including citramalic acid, tartaric acid and tricarballylic acid, were not statistically significant.

The results support the existence of a yeast-associated subgroup, but not a major role for yeast in most autistic children.

 

7. The quantitative data support a lower prevalence than the headline claim

The paper's headline message is that approximately 90% of autistic children have elevated microbial metabolites.

However, the quantitative data suggest:

  • 57% with elevated phenylalanine-related metabolites
  • 42% with elevated tryptophan-related metabolites
  • 16% with elevated yeast metabolites
  • 78% with at least one elevated microbial metabolite

The validated figure is therefore closer to 78% than 90%.

 

8. A possible aromatic amino acid subtype of autism

Taken together, the clearest pattern involves metabolites derived from phenylalanine, tyrosine and tryptophan.

These amino acids are precursors for important neurotransmitters including:

  • Dopamine
  • Noradrenaline
  • Serotonin
  • Melatonin

The study therefore suggests that a substantial subgroup of autistic children may have altered microbial metabolism of aromatic amino acids. This broader observation may ultimately prove more important than any individual metabolite measured in the study.

What matters clinically?

The most important question raised by these findings is not whether they can be used to diagnose autism. The more important question is whether these metabolites are merely biomarkers or whether they contribute directly to symptoms.

If elevated p-cresol sulfate, p-cresol, phenylacetylglutamine or indoxyl sulfate prove to be biologically active drivers of symptoms, then they become potential treatment targets. This would fit with a growing body of evidence suggesting that at least some forms of autism involve treatable metabolic and physiological abnormalities.

From a personalized medicine perspective, the most valuable contribution of this study is not the proposed diagnostic test but the identification of potentially actionable metabolic pathways that may define a distinct subgroup of autistic individuals.

 

Conclusion

This study provides further evidence that abnormal microbial metabolites are common in autism and may define a biologically meaningful subtype.

The findings are intriguing and broadly consistent with decades of research on p-cresol and other gut-derived compounds.

However, the study does not prove that gut dysbiosis causes autism, nor does it establish a clinically validated screening test.

What it does provide is another reminder that autism is heterogeneous and that meaningful progress is likely to come from identifying and treating specific biological abnormalities rather than assuming that all autistic people share the same underlying pathology.

For those interested in personalized medicine, that is perhaps the most important message of all.

 

How might altered microbial metabolism of aromatic amino acids be treated?

The study suggests that a substantial subgroup of autistic children have abnormal microbial metabolism of the aromatic amino acids phenylalanine, tyrosine and tryptophan, leading to elevated levels of compounds such as p-cresol, p-cresol sulfate, phenylacetylglutamine and indoxyl sulfate. While no proven treatment exists specifically for this metabolic pattern, several approaches could potentially be helpful.

The most obvious strategy is to modify the gut microbiome itself through dietary changes, prebiotics, probiotics, synbiotics or, in selected cases, Microbiota Transfer Therapy (MTT). The goal would be to reduce production of potentially harmful metabolites and encourage a healthier microbial ecosystem.

Another approach is to increase populations of beneficial bacteria that preferentially ferment dietary fiber into short-chain fatty acids such as butyrate rather than producing aromatic metabolites.

Improving intestinal barrier function may also reduce absorption of microbial metabolites into the bloodstream. Compounds such as butyrate and some probiotics have been proposed for this purpose.

Since several of the metabolites identified in the study are sulfate conjugates, supporting sulfation and glutathione pathways through interventions such as NAC or taurine may also deserve further investigation.

Because p-cresol and related compounds have been linked to oxidative stress and mitochondrial dysfunction, mitochondrial support therapies may help reduce downstream effects even if they do not address the underlying source of the metabolites.

Finally, gastrointestinal motility should not be overlooked. Chronic constipation increases the time available for bacterial fermentation of amino acids and may contribute to the production of p-cresol and related compounds. Treating constipation and other gastrointestinal problems may therefore be an important part of the solution.

At present, the evidence is strongest for identifying these metabolites as biomarkers rather than proven treatment targets. The key question for future research is whether reducing elevated microbial metabolites leads to meaningful improvements in autism symptoms, gastrointestinal function and quality of life.